# Nelitolimod

Source: https://onco.cc/drugs/nelitolimod/  
OnCo record `nelitolimod` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nelitolimod is an experimental immune-stimulating drug from TriSalus Life Sciences, in phase 1 trials for locally advanced pancreatic cancer and cancers in the liver.

## Summary

Nelitolimod (SD-101) is a tLR9 agonist (immunotherapy), given through the company's pressure-enabled drug delivery devices from TriSalus Life Sciences. Switches on toll-like receptor 9; the company says it acts on suppressive myeloid cells and antigen-presenting cells to reverse immune suppression in the liver and pancreas so that checkpoint inhibitors can work. TriSalus acquired it in 2020. Its studies were in locally advanced pancreatic cancer (NCT05607953), hepatocellular carcinoma and intrahepatic cholangiocarcinoma (NCT05220722, terminated) and uveal melanoma that has spread to the liver (NCT04935229, terminated). OnCo has no TLR9 target record. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: SD-101
- Tags: pipeline; ctgov-ingest
- Code: SD-101
- Modality: TLR9 agonist (immunotherapy), given through the company's pressure-enabled drug delivery devices
- Mechanism: Switches on toll-like receptor 9; the company says it acts on suppressive myeloid cells and antigen-presenting cells to reverse immune suppression in the liver and pancreas so that checkpoint inhibitors can work.

## Sources

- TriSalus pipeline: https://trisaluslifesci.com/pipeline/
- TriSalus nelitolimod: https://trisaluslifesci.com/candidate-nelitolimod/
- ClinicalTrials.gov NCT05607953: https://clinicaltrials.gov/study/NCT05607953
- ClinicalTrials.gov NCT05220722: https://clinicaltrials.gov/study/NCT05220722
- ClinicalTrials.gov NCT04935229: https://clinicaltrials.gov/study/NCT04935229

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- companies: [TriSalus Life Sciences](https://onco.cc/companies/trisalus-life-sciences/)
- trials: [Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma](https://onco.cc/trials/nct04935229/), [Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors](https://onco.cc/trials/nct05220722/), [Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma](https://onco.cc/trials/nct05607953/)

---
JSON: https://onco.cc/api/v1/entities/nelitolimod.json